Intellia Therapeutics CEO John Leonard Sells Company Shares
1 report, 1 independent
Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
John Leonard, CEO of Intellia Therapeutics, sold 9,000 shares of the company's stock on November 2, 2026, at an average price of $11.99, totaling $107,910.00. This transaction represented a 0.78% decrease in his ownership of the stock. Following the sale, his remaining shares were valued at $13,645,387.36.
From tickerreport.com
Why it matters
The sale was disclosed in a filing with the Securities & Exchange Commission. The transaction occurred while Intellia Therapeutics stock was trading near $11.86, after the company reported quarterly revenue of $7.66 million, which missed analyst estimates of $12.98 million.
From tickerreport.com
Who's involved
- Intellia TherapeuticsBiotechnology company whose stock was traded
- John LeonardChief Executive Officer who sold the company shares
- Regeneron PharmaceuticalsAmerican pharmaceutical company collaborating with Intellia Therapeutics
- NasdaqStock exchange where Intellia Therapeutics is listed
Keep exploring
The entities involved
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
Nothing else this week.